Edition:
United Kingdom

Juniper Pharmaceuticals Inc (JNP.OQ)

JNP.OQ on NASDAQ Stock Exchange Global Select Market

4.95USD
8:26pm GMT
Change (% chg)

$-0.15 (-2.94%)
Prev Close
$5.10
Open
$5.15
Day's High
$5.15
Day's Low
$4.93
Volume
1,136
Avg. Vol
4,579
52-wk High
$6.10
52-wk Low
$3.65

Latest Key Developments (Source: Significant Developments)

Juniper Pharmaceuticals reports third quarter results
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Juniper Pharmaceuticals Inc :Juniper Pharmaceuticals reports third quarter 2017 financial and operating results.Q3 loss per share $0.13.Q3 revenue rose 12 percent to $13 million.  Full Article

Juniper Pharmaceuticals Q2 loss per share $0.16
Thursday, 4 Aug 2016 

Juniper Pharmaceuticals Inc : Juniper Pharmaceuticals reports second quarter 2016 financial results . Q2 revenue $11.9 million . Q2 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.16 . Q2 revenue view $9.5 million -- Thomson Reuters I/B/E/S . Anticipates full-year 2016 revenue growth in low- to mid-teen percentage range over 2015 result .Now anticipates full-year 2016 revenue growth in low- to mid-teen percentage range over 2015 results.  Full Article

Juniper Pharmaceuticals appoints CEO
Wednesday, 20 Jul 2016 

Juniper Pharmaceuticals Inc : Secor will also be appointed to board of directors . Juniper Pharmaceuticals appoints Alicia Secor president and chief executive officer . Secor will also be appointed to board of directors .Secor succeeds Frank Condella, who announced his intent to retire as Juniper's president and CEO earlier this year..  Full Article

Juniper Pharmaceuticals completes enrollment in phase 2b clinical trial of COl-1077, 10 pct lidocaine vaginal gel
Thursday, 7 Jul 2016 

Juniper Pharmaceuticals Inc : Juniper pharmaceuticals announces completion of enrollment in phase 2b clinical trial of col-1077 10% lidocaine vaginal gel for gynecologic procedure pain .Remains on track to report top-line data from study in q3 of 2016.  Full Article

Juniper Pharmaceuticals says CEO Frank Condella to retire
Thursday, 2 Jun 2016 

Juniper Pharmaceuticals Inc : Juniper Pharmaceuticals announces planned retirement of CEO Frank Condella . Condella will continue to serve as president and CEO until his successor is in place . Search for his successor is underway .Remains on track to report results of multi-center double-blind Phase 2B trial evaluating col-1077 in Q3 of 2016.  Full Article

BRIEF-Juniper Pharmaceuticals reports third quarter results

* Juniper Pharmaceuticals reports third quarter 2017 financial and operating results